Guselkumab Dose 2

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

Crohn's DiseaseColitis, Ulcerative

97 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

1

Tremfya

Johnson & Johnson

Phase 3

112

Omvoh

Eli Lilly

Phase 3

63

Leukine

Sanofi

Phase 3

44

Thalomid

Bristol-Myers Squibb

Phase 3

35

Mounjaro

Eli Lilly

Phase 3

26

Jyseleca

Gilead

Phase 3

27

Rinvoq

AbbVie

Phase 3

28

Biaxin

AbbVie

Phase 3

19

Orencia

Bristol-Myers Squibb

Phase 3

110

Velsipity

Pfizer

Phase 3

1Show 40 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Colitis, Ulcerative1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting·Johnson & Johnson·Phase 3·NCT05528510·418 enrolled

Crohn's Disease1 trial

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Active, not recruiting·Johnson & Johnson·Preclinical·NCT03466411·1,409 enrolled

Details

Drug Info

Related News